Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.81
-0.16 (-2.68%)
At close: Mar 28, 2025, 4:00 PM
5.76
-0.05 (-0.86%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Revenue
In the year 2024, Recursion Pharmaceuticals had annual revenue of $58.84M with 32.00% growth. Recursion Pharmaceuticals had revenue of $4.55M in the quarter ending December 31, 2024, a decrease of -58.26%.
Revenue (ttm)
$58.84M
Revenue Growth
+32.00%
P/S Ratio
27.08
Revenue / Employee
$73,549
Employees
800
Market Cap
2.34B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RXRX News
- 25 days ago - Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says - Benzinga
- 4 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th - GlobeNewsWire
- 5 weeks ago - Altitude Lab Startups Raise $154M in Capital - GlobeNewsWire
- 6 weeks ago - Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off - Seeking Alpha
- 7 weeks ago - Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference - GlobeNewsWire
- 2 months ago - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More - GlobeNewsWire